Idarrubicina Azevedos (Idarubicin Hydrochloride)

Idarubicin intercalates into DNA and blocks topoisomerase II, causing double‑strand DNA breaks. It also generates free radicals that damage cellular membranes. These mechanisms lead to apoptosis of rapidly dividing cancer cells, particularly leukemic blasts.

The dosing regimen for Idarrubicina Azevedos is determined by the prescribing oncologist based on the patient’s disease characteristics, body surface area, and treatment protocol. Only a qualified healthcare professional should set the dose and schedule.

Idarubicin is classified as contraindicated in pregnancy because it can cause fetal harm. It is also excreted in breast milk and may affect the infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative therapies with their physician.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Idarubicin is chemically related to doxorubicin but is more lipophilic, allowing better cellular uptake and potentially higher potency against certain leukemias. Compared with other anthracyclines, it may have a slightly different toxicity profile, especially regarding cardiac effects, but overall efficacy is comparable within approved regimens.

Idarrubicina Azevedos should be stored at 2‑8 °C in a refrigerator, protected from light. The product must not be frozen or shaken. Keep the vial in its original packaging until use to maintain stability.

The drug is given by intravenous infusion under the supervision of a qualified healthcare professional. Administration is typically performed in a hospital or oncology clinic, following aseptic technique and appropriate infusion rate as directed by the treatment protocol.

The most serious risks include cardiotoxicity (which can lead to heart failure), severe myelosuppression resulting in infections or bleeding, and the potential for secondary malignancies such as therapy‑related acute leukemia. Close monitoring of cardiac function and blood counts is essential.

Patients with pre‑existing severe cardiac disease, uncontrolled infections, or known hypersensitivity to idarubicin or other anthracyclines should avoid this medication. It is also contraindicated in pregnant women and should be used with caution in the elderly or those with impaired liver function.